Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RVL Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.33.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, RVL Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.
The historical rank and industry rank for RVL Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
RVLPQ's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 7.03 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
RVL Pharmaceuticals Cash-to-Debt Related Terms
RVL Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for RVL Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
RVLPQ vs SNPX, THAR, SLRX: Cash-to-Debt Comparison
For the Biotechnology subindustry, RVL Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RVL Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where RVL Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVL Pharmaceuticals (RVLPQ) has a Cash-to-Debt of 0.33 as of Jun. 2023.
Is RVL Pharmaceuticals' Cash-to-Debt too high?
RVL Pharmaceuticals' current Cash-to-Debt is 0.33. The Biotechnology industry median Cash-to-Debt is 7.03. RVL Pharmaceuticals' value of 0.33 is 95.3% below this industry median. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Cash-to-Debt compare to SNPX and THAR?
RVL Pharmaceuticals' Cash-to-Debt of 0.33 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 7.03. RVL Pharmaceuticals' value of 0.33 is 95.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RVL Pharmaceuticals's current Cash-to-Debt of 0.33 is 95.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RVL Pharmaceuticals's current Cash-to-Debt is 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Cash-to-Debt of 0.33. The current Cash-to-Debt is 0.33 and 95.3% below the Biotechnology industry median of 7.03. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Cash-to-Debt is 0.33 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score
Get the complete analysis for RVLPQ
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVLPQ has been successfully added to your 
